JP2012510987A5 - - Google Patents

Download PDF

Info

Publication number
JP2012510987A5
JP2012510987A5 JP2011539117A JP2011539117A JP2012510987A5 JP 2012510987 A5 JP2012510987 A5 JP 2012510987A5 JP 2011539117 A JP2011539117 A JP 2011539117A JP 2011539117 A JP2011539117 A JP 2011539117A JP 2012510987 A5 JP2012510987 A5 JP 2012510987A5
Authority
JP
Japan
Prior art keywords
zaleplon
dosage form
biodegradable
layer
gastroretentive dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011539117A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012510987A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2009/007731 external-priority patent/WO2010064139A2/en
Publication of JP2012510987A publication Critical patent/JP2012510987A/ja
Publication of JP2012510987A5 publication Critical patent/JP2012510987A5/ja
Pending legal-status Critical Current

Links

JP2011539117A 2008-12-04 2009-10-19 ザレプロン胃内滞留性薬剤送達システム Pending JP2012510987A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12005108P 2008-12-04 2008-12-04
US61/120,051 2008-12-04
PCT/IB2009/007731 WO2010064139A2 (en) 2008-12-04 2009-10-19 Zaleplon gastroretentive drug delivery system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014231788A Division JP6104873B2 (ja) 2008-12-04 2014-11-14 ザレプロン胃内滞留性薬剤送達システム

Publications (2)

Publication Number Publication Date
JP2012510987A JP2012510987A (ja) 2012-05-17
JP2012510987A5 true JP2012510987A5 (enExample) 2012-12-06

Family

ID=42232930

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011539117A Pending JP2012510987A (ja) 2008-12-04 2009-10-19 ザレプロン胃内滞留性薬剤送達システム
JP2014231788A Expired - Fee Related JP6104873B2 (ja) 2008-12-04 2014-11-14 ザレプロン胃内滞留性薬剤送達システム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014231788A Expired - Fee Related JP6104873B2 (ja) 2008-12-04 2014-11-14 ザレプロン胃内滞留性薬剤送達システム

Country Status (11)

Country Link
US (2) US9693981B2 (enExample)
EP (1) EP2378883B1 (enExample)
JP (2) JP2012510987A (enExample)
KR (1) KR20110116004A (enExample)
CN (1) CN102300463B (enExample)
CA (1) CA2745741A1 (enExample)
ES (1) ES2562925T3 (enExample)
IL (1) IL213376A (enExample)
PL (1) PL2378883T3 (enExample)
WO (2) WO2010064139A2 (enExample)
ZA (1) ZA201104620B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2276473T (lt) 2008-04-18 2017-02-27 Intec Pharma Ltd. Pailginto atpalaidavimo vaistų karbidopa/levodopa įvedimas
UA108211C2 (uk) * 2009-11-04 2015-04-10 Янссен Рід Айрленд Бензімідазолімідазольні похідні
EP2575798B1 (en) * 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosage forms of gaba analogs
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
TR201809351T4 (tr) * 2011-03-01 2018-07-23 Pharnext Nörolojik bozuklukların baklofen ve akamprosat tabanlı terapisi.
US9180108B2 (en) 2011-10-27 2015-11-10 Medtronic, Inc. Baclofen formulations and methods for making same
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
EP2854774A4 (en) 2012-06-01 2015-11-18 Lynn Health Science Inst Inc METHODS OF TREATING INSOMNIA
WO2014039951A1 (en) * 2012-09-10 2014-03-13 Novartis Ag Enteral pharmaceutical compositions
CN105431144A (zh) 2013-06-05 2016-03-23 思康脑侒股份有限公司 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
JP6392355B2 (ja) 2013-09-13 2018-09-19 アール.ピー.シェーラー テクノロジーズ、エルエルシー ペレット包含錠剤
FR3014692B1 (fr) * 2013-12-18 2016-01-29 Ethypharm Sa Compositions pharmaceutiques orales a retention gastrique.
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
CN116370644A (zh) 2014-06-11 2023-07-04 麻省理工学院 驻留结构及相关方法
JP6956009B2 (ja) * 2014-12-29 2021-10-27 ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. 化学療法剤の多段階放出のための組成物、装置、および方法
US9579289B2 (en) 2015-02-20 2017-02-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
AU2016342374B2 (en) 2015-10-23 2022-08-04 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
CN108697649A (zh) 2015-12-08 2018-10-23 林德拉有限公司 用于胃驻留系统的几何构型
CN119925721A (zh) 2016-05-27 2025-05-06 林德拉治疗公司 用于胃驻留系统的材料结构
JP2019527208A (ja) * 2016-07-11 2019-09-26 インテック ファーマ リミテッド 経口胃保持製剤及びその使用
CN118766834A (zh) 2016-09-30 2024-10-15 林德拉治疗公司 用于金刚烷类药物缓释的胃驻留系统
CA3060026A1 (en) * 2017-04-18 2018-10-25 Jayant Jagannath Khandare Polymer based formulation for release of drugs and bioactives at specific git sites
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2018227147A1 (en) 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
KR102333609B1 (ko) * 2017-10-31 2021-12-01 주식회사 삼양홀딩스 붕해가 개선된 경구용 고형 제제 조성물 및 이의 제조 방법
CA3134186A1 (en) * 2019-03-20 2020-09-24 Lyndra Therapeutics, Inc. Coatings for gastric residence dosage forms
JP2022525926A (ja) * 2019-03-20 2022-05-20 リンドラ セラピューティクス, インコーポレイティド 胃内滞留剤形用のカプセル及びカプセルコーティング
US11654124B2 (en) 2019-07-29 2023-05-23 Amneal Pharmaceuticals Llc Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
US10792262B1 (en) 2019-07-29 2020-10-06 Saol International Limited Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives
WO2021138495A1 (en) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particles for multi-dose delivery
US11491125B1 (en) 2021-09-29 2022-11-08 Amneal Pharmaceuticals Llc Baclofen formulations and methods of minimizing patient exposure to metabolite variations
WO2023141524A2 (en) * 2022-01-19 2023-07-27 Lyndra Therapeutics, Inc. Dosage forms for gastric retention

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451260A (en) * 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
US4767627A (en) 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
JPH07179334A (ja) * 1993-12-22 1995-07-18 Sanei Touka Kk カプセル及びカプセル剤の製造方法
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
IL133196A0 (en) * 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
DE10004790B4 (de) * 2000-02-01 2004-09-09 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung von Zaleplon, Verfahren zu seiner Herstellung und seine Verwendung
KR20040018394A (ko) 2001-07-04 2004-03-03 썬 파마슈티컬 인더스트리스 리미티드 위 정체 제어되는 약물 전달 계
US20080081834A1 (en) * 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20050038042A1 (en) * 2002-11-15 2005-02-17 Jenet Codd Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
AU2003301121A1 (en) * 2002-12-18 2004-07-14 Pain Therapeutics, Inc. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
KR100553887B1 (ko) * 2003-06-24 2006-02-24 삼성전자주식회사 수직 및 수평으로 광시야각을 갖는 영상표시용 스크린 및이를 구비하는 프로젝션 텔레비전
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
EP1523981A1 (en) * 2003-10-13 2005-04-20 Wyeth Extended release formulations of venlafaxine
WO2005044199A2 (en) * 2003-11-05 2005-05-19 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
EP1535952B1 (en) * 2003-11-28 2013-01-16 Universite Louis Pasteur Method for preparing crosslinked polyelectrolyte multilayer films
US20050220874A1 (en) * 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
JP4756835B2 (ja) * 2004-07-14 2011-08-24 キヤノン株式会社 生化学反応カートリッジ
US20080299204A1 (en) * 2005-06-23 2008-12-04 Spherics, Inc. Dosage forms for movement disorder treatment
BRPI0620328A2 (pt) * 2005-12-23 2011-11-08 Cadbury Adams Usa Llc composições que proporcionam uma sensação substancialmente similar à proporcionada pelo mentol
JP5399715B2 (ja) 2006-01-18 2014-01-29 インテック ファーマ リミテッド 薬剤の経口摂取用の送達デバイスを形成する方法および装置
CA2642479C (en) 2006-02-15 2014-08-19 Intec Pharma Ltd. A gastro-retentive system for the delivery of macromolecules
US8765178B2 (en) * 2006-07-19 2014-07-01 Watson Laboratories, Inc. Controlled release formulations and associated methods
US20080206332A1 (en) * 2007-01-11 2008-08-28 Kidney David J Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
EP1970056A1 (en) * 2007-03-15 2008-09-17 Polichem S.A. Time-specific delayed/pulsatile release dosage forms
US20100137442A2 (en) * 2008-02-01 2010-06-03 Xenoport, Inc. Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment

Similar Documents

Publication Publication Date Title
JP2012510987A5 (enExample)
JP6104873B2 (ja) ザレプロン胃内滞留性薬剤送達システム
CN111405895B (zh) 一种控释药物组合物及其制备方法
AU2008282900B2 (en) Pulsatile gastric retentive dosage forms
JP6062465B2 (ja) カルビドパ/レボドパ胃内滞留性薬物供給
JP2015028094A5 (enExample)
TWI324075B (en) Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
RU2554740C2 (ru) Композиции перорально распадающихся таблеток, содержащие комбинации высоко- и низкодозовых лекарственных средств
Dehghan et al. Gastroretentive drug delivery systems: A patent perspective
JP5161071B2 (ja) 胃酸分泌
RU2008151949A (ru) Фармацевтические лекарственные формы и композиции фенилэфрина для абсорбции в ободочной кишке
JP2014240435A (ja) 胃酸分泌を阻害するための組成物および方法
AU2009333300A1 (en) Oral formulations
EP3866758B1 (en) Softgels with solid or gel-like polymeric fill matrix
JP2008516893A (ja) 多層錠剤および生体接着性剤形
CN104379138A (zh) 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合
Rabadia et al. The floating drug delivery system and its impact on calcium channel blocker: A review article
JP2017511350A5 (enExample)
Jain et al. An Insight on the Strategical Approach of Gastro-retentive Drug Delivery System
JP5191121B2 (ja) 溶解性を改善したジフェンヒドラミン含有医薬組成物
Benzine Enzymatically triggered polymeric drug delivery systems for colon targeting
JP2013006843A (ja) 胃酸分泌
Thitinan Development of multiple dose platforms for oral drug delivery
WO2007010846A1 (ja) 胃内滞留製剤